American Century Companies Inc. Grows Stock Holdings in Bioventus Inc. $BVS

American Century Companies Inc. raised its stake in Bioventus Inc. (NYSE:BVS) by 7.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,124,041 shares of the company’s stock after buying an additional 79,829 shares during the period. American Century Companies Inc. owned approximately 1.37% of Bioventus worth $7,441,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. increased its stake in Bioventus by 23,761.5% in the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company’s stock valued at $57,000 after purchasing an additional 6,178 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Bioventus in the second quarter valued at $72,000. Police & Firemen s Retirement System of New Jersey increased its position in shares of Bioventus by 55.9% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,768 shares of the company’s stock valued at $78,000 after buying an additional 4,221 shares in the last quarter. PDT Partners LLC acquired a new position in shares of Bioventus during the 1st quarter worth $120,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bioventus by 35.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,181 shares of the company’s stock worth $157,000 after buying an additional 4,513 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Insider Activity at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 17,701 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $7.42, for a total value of $131,341.42. Following the sale, the director directly owned 56,997 shares in the company, valued at $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 33.00% of the stock is owned by corporate insiders.

Bioventus Price Performance

Shares of NYSE BVS opened at $7.09 on Friday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The company’s 50-day moving average price is $7.08 and its 200 day moving average price is $6.93. Bioventus Inc. has a 52 week low of $5.81 and a 52 week high of $11.89. The stock has a market cap of $586.79 million, a price-to-earnings ratio of -11.62 and a beta of 0.79.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.